Chronic Insomnia Epidemiology

• Insomnia affects nearly 30% of the US population, with approximately 5% to 15% meeting criteria for chronic insomnia. It is associated with substantial impairment in quality of life, reduced productivity, and persistent fatigue and daytime drowsiness, while also increasing the risk of developing comorbid health conditions.
• Reduced sleep duration in chronic insomnia is associated with a significantly elevated risk of cardiometabolic conditions, including coronary artery disease, myocardial infarction, type 2 diabetes, obesity, and systemic hypertension, as well as increased all-cause mortality. It is also linked to a higher risk of developing psychiatric disorders, underscoring its broad systemic impact.
• Although chronic insomnia affects approximately 20–30% of children, with prevalence rising to as high as 86% in those with neurodevelopmental conditions, its clinical presentation varies markedly across different age groups.
• According to the International Classification of Sleep Disorders, 3rd edition criteria, insomnia is defined as complaints of Difficulty Initiating Sleep (DIS), and/or Difficulty Maintaining Sleep (DMS), and/or Early Morning Awakenings (EMA). These nocturnal symptoms must be accompanied by daytime impairment related to sleeping difficulties.

Chronic Insomnia Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalence of Chronic Insomnia: XX million
• 2036 Projected Diagnosed Prevalence Cases of Chronic Insomnia: XX million
• Chronic Insomnia Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Chronic Insomnia– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chronic Insomnia Understanding and Diagnosis Algorithm

Chronic Insomnia Overview and Diagnosis

Chronic insomnia is the most prevalent sleep disorder, affecting up to 10% of the global population, while more than one-third of individuals worldwide report insufficient sleep as a frequent concern. Given its high burden, insomnia commonly co-occurs with both somatic and psychiatric conditions, often in a bidirectional relationship where each worsens the other. Disorders such as depression, anxiety, cardiovascular disease, and malignancies may act as key triggers for insomnia, consistent with behavioral models of its development.

Conversely, chronic insomnia is not merely a symptom but a contributing risk factor for these conditions. It is linked to multiple pathogenic pathways, including sustained activation of the stress response system, dysregulated neurotransmitter signaling, and impaired emotional regulation. Together, these mechanisms position insomnia as both a consequence and a driver of broader systemic disease.

Chronic Insomnia Diagnosis

Diagnosis of chronic insomnia involves a structured clinical evaluation to identify underlying causes and associated conditions. This typically includes a physical examination to detect medical contributors, with laboratory tests such as thyroid function assessment when indicated. A detailed review of sleep habits is essential, using clinical interviews, questionnaires, and sleep diaries to assess sleep–wake patterns and daytime impairment. When the diagnosis remains unclear, or a coexisting sleep disorder such as sleep apnea or restless legs syndrome is suspected, an overnight sleep study (polysomnography) may be performed to monitor physiological parameters, including brain activity, breathing, heart rate, and body movements during sleep.

Further details are provided in the report.

Chronic Insomnia Epidemiology

Key Findings from Chronic Insomnia Epidemiological Analysis and Forecast 

• In 2025, diagnosed prevalent cases of insomnia across the 7MM were estimated at approximately 88 million. 
• Among the 7MM, the US had the highest number of cases of insomnia, followed by France, Japan, and Germany in 2025.
• In 2025, age-specific diagnosed prevalent cases of insomnia showed the highest prevalence among individuals aged ≥65, with nearly 2.2 million cases, and the lowest among those aged 18–24, with approximately 300,000 cases in Japan.
• According to the American Academy of Sleep Medicine (2024), approximately 12% of Americans have been diagnosed with chronic insomnia.
• In 2025, France represented the highest number of diagnosed prevalent cases of insomnia among the EU4 and the UK, accounting for nearly 10 million cases alone, while Spain reported the lowest number of cases. 

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Chronic Insomnia, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Chronic Insomnia Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by Geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Chronic Insomnia? What will be the growth opportunities across the 7MM concerning the patient population with Chronic Insomnia?
• What is the historical and forecasted Chronic Insomnia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.